An alkaline comet assay study on the antimalarial drug atovaquone in human peripheral blood lymphocytes: A study based on clinically relevant concentrations

Journal of Applied Toxicology

Volumn 33, Issue 1, 2013, Pages 56-62

  Dinter, Domagoj ^a   Gajski, Goran ^b   Garaj Vrhovac, Vera ^b  

^a PLIVA CROATIA LTD   (Croatia)

^b INSTITUTE FOR MEDICAL RESEARCH AND OCCUPATIONAL HEALTH   (Croatia)

Author keywords

Atovaquone; Clinically relevant concentrations; Comet assay; Cytotoxicity; Genotoxicity; Human peripheral blood lymphocytes

Indexed keywords

ATOVAQUONE; ATOVAQUONE PLUS PROGUANIL; DRUG METABOLITE;

ADULT; APOPTOSIS; ARTICLE; CELL VIABILITY; COMET ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOGENETICS; DRUG CYTOTOXICITY; DRUG SAFETY; GENOTOXICITY; HUMAN; HUMAN CELL; MALARIA; METABOLIC ACTIVATION; NORMAL HUMAN; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

ADULT; ANTIMALARIALS; ATOVAQUONE; CELL SURVIVAL; COMET ASSAY; DNA DAMAGE; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME ACTIVATION; HUMANS; LYMPHOCYTES; MALE; MUTAGENS; RIBOSOMAL PROTEINS;

EID: 84870392825     PISSN: 0260437X     EISSN: 10991263     Source Type: Journal    
DOI: 10.1002/jat.1711     Document Type: Article

References (47)

1. Abou-Eisha A, Afifi M. 2004. Genotoxic evaluation of the antimalarial drug, fansidar, in cultured human lymphocytes. Cell Biol. Toxicol. 20: 303-311; doi: 10.1007/s10565-004-5352-4.
2. AlKadi HO. 2007. Antimalarial drug toxicity: a review. Chemotherapy 53: 385-391; doi: 10.1159/000109767.
3. Artymowicz RJ, James VE. 1998. Atovaquone: a new antipneumocystis agent. Clin. Pharm. 12: 563-570.
4. Baggish AL, Hill DR. 2002. Antiparasitic agent atovaquone. Antimicrob. Agents Chemother. 46: 1163-1173; doi: 10.1128/AAC.46.5.1163-1173.2002.
5. Berman JD, Nielsen R, Chulay JD, Dowler M, Kain KC, Kester KE, Williams J, Whelen AC, Shmuklarsky MJ. 2001. Causal prophylactic efficacy of atovaquone-proguanil (Malarone) in a human challenge model. Trans. R. Soc. Trop. Med. Hyg. 95: 429-432; doi: 10.1016/S0035-9203(01)90206-8.
6. Chattopadhyay R, Mahajan B, Kumar S. 2007. Assessment of safety of the major antimalarial drugs. Expert Opin. Drug. Saf. 6: 505-521; doi: 10.1517/14740338.6.5.505.
7. Chulay JD. 1998. Challenges in the development of antimalarial drugs with causal prophylactic activity. Trans. R. Soc. Trop. Med. Hyg. 92: 577-579; doi: 10.1016/S0035-9203(98)90772-6.
8. Collins AR, Oscoz AA, Brunborg G, Gaivão I, Giovannelli L, Kruszewski M, Smith CC, Stetina R. 2008. The comet assay: topical issues. Mutagenesis 23: 143-151; doi: 10.1093/mutage/gem051.
9. Danis M, Bricaire F. 2003. The new drug combinations: their place in the treatment of uncomplicated Plasmodium falciparum malaria. Fund. Clin. Pharmacol. 17: 155-160; doi: 10.1046/j.1472-8206.2003.00165.x.
10. Dhanawat M, Das N, Nagarwal RC, Shrivastava SK. 2009. Antimalarial drug development: past to present scenario. Mini. Rev. Med. Chem. 9: 1447-1469; doi: 10.2174/138955709789957323.
11. Duke RC, Cohen JJ. 1992. Morphological and biochemical assays of apoptosis. In Current Protocols in Immunology, Coligan JE, Kruisbeal AM (eds). Wiley: New York; 1-3.
12. Dusinska M, Collins AR. 2008. The comet assay in human biomonitor ing: gene-environment interactions. Mutagenesis. 23: 191-205; doi: 10.1093/mutage/gen007.
13. El Hage S, Ane M, Stigliani JL, Marjorie M, Vial H, Baziard-Mouysset G, Payard M. 2009. Synthesis and antimalarial activity of new atovaquone derivatives. Eur. J. Med. Chem. 44: 4778-4782; doi: 10.1016/j.ejmech.2009.07.021.
14. Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxynaphthoquinone, 2-[trans-4-(4′-chlorophenyl) cyclohexyl]-3-hydroxy-1, 4-naphthoquinone (566C80). Biochem. Pharmacol. 43: 1545-1553; doi: 10.1016/0006-2952(92)90213-3.
15. Gajski G, Garaj-Vrhovac V, Oreščanin V. 2008. Cytogenetic status and oxidative DNA-damage induced by atorvastatin in human peripheral blood lymphocytes: standard and Fpg-modified comet assay. Toxicol. Appl. Pharmacol. 231: 85-93; doi: 10.1016/j.taap.2008.03.013.
16. Gajski G, Dinter D, Garaj-Vrhovac V. 2010. In vitro effect of the antimalarial drug proguanil hydrochloride on viability and DNA damage in human peripheral blood lymphocytes. Environ. Toxicol. Pharmacol. 30: 257-263; doi: 10.1016/j.etap.2010.07.001.
17. Garaj-Vrhovac V, Oreščanin V. 2009. Assessment of DNA sensitivity in peripheral blood leukocytes after occupational exposure to microwave radiation: the alkaline comet assay and chromatid breakage assay. Cell. Biol. Toxicol. 25: 33-43; doi: 10.1007/s10565-008-9060-3.
18. GlaxoSmithKline. 2001. Malarone. Material safety data sheet. Available from: http://www.msds-gsk.com.
19. GlaxoSmithKline. 2009. Malarone atovaquone and proguanil hydrochloride. Prescribing information. Available from: http://www.gsk.com.
20. Haile LG, Flaherty JF. 1993. Atovaquone: a review. Ann. Pharmacother. 27: 1488-1494.
21. Henderson L, Wolfreys A, Fedyk J, Bourner C, Windebank S. 1998. The ability of the comet assay to discriminate between genotoxins and cytotoxins. Mutagenesis. 13: 89-94.
22. Kain KC. 2003. Atovaquone/proguanil: the need for family protection. J. Travel. Med. 10: 8-12; doi: 10.1093/mutage/13.1.89.
23. Kessl JJ, Hill P, Lange BB, Meshnick SR, Meunier B, Trumpower BL. 2004. Molecular basis for atovaquone resistance in Pneumocystis jirovecii modeled in the cytochrome bc(1) complex of Saccharomyces cerevisiae. J. Biol. Chem. 279: 2817-2824; doi: 10.1074/jbc.M309984200.
24. Korsinczky M, Chen N, Kotecka B, Saul A, Rieckmann K, Cheng Q. 2000. Mutations in Plasmodium falciparum cytochrome b that are associated with atovaquone resistance are located at a putative drug-binding site. Antimicrob. Agents Chemother. 44: 2100-2108; doi: 10.1128/AAC.44.8.2100-2108.2000.
25. Looareesuwan S, Chulay JD, Canfield CJ, Hutchinson DB. 1999. Malarone (atovaquone and proguanil hydrochloride): a review of its clinical development for treatment of malaria. Am. J. Trop. Med. Hyg. 60: 533-541.
26. McArt DG, McKerr G, Howard CV, Saetzler K, Wasson GR. 2009. Modelling the comet assay. Biochem. Soc. Trans. 37: 914-917; doi: 10.1042/BST0370914.
27. McFadden DC, Tomavo S, Berry EA, Boothroyd JC. 2000. Characterization of cytochrome b from Toxoplasma gondii and Q(o) domain mutations as a mechanism of atovaquone-resistance. Mol. Biochem. Parasitol. 108: 1-12; doi: 10.1016/S0166-6851(00)00184-5.
28. McKeage K, Scott L. 2003. Atovaquone/proguanil: a review of its use for the prophylaxis of Plasmodium falciparum malaria. Drugs. 63: 597-623; doi: 10.2165/00003495-200363060-00006.
29. Mehlotra RK, Henry-Halldin CN, Zimmerman PA. 2009. Application of pharmacogenomics to malaria: a holistic approach for successful chemotherapy. Pharmacogenomics 10: 435-449; doi: 10.2217/1462216.10.3.435.
30. Miller JL, Trepanier LA. 2002. Inhibition by atovaquone of CYP2C9-mediated sulphamethoxazole hydroxylamine formation. Eur. J. Clin. Pharmacol. 58: 69-72; doi: 10.1007/s00228-002-0424-y.
31. Nzila A, Chilengi R. 2010. Modulators of the efficacy and toxicity of drugs in malaria treatment. Trends Pharmacol. Sci. 31: 277-283; doi: 10.1016/j.tips.2010.03.002.
32. Olive PL, Frazer G, Banáth JP. 1993. Radiation-induced apoptosis measured in TK6 human B lymphoblast cells using the comet assay. Radiat. Res. 136: 130-136; doi: 10.2307/3578650.
33. Olliaro P. 2001. Mode of action and mechanisms of resistance for antimalarial drugs. Pharmacol. Ther. 89: 207-219; doi: 10.1016/S0163-7258(00)00115-7.
34. Patel SN, Kain KC. 2005. Atovaquone/proguanil for the prophylaxis and treatment of malaria. Expert Rev. Anti. Infect. Ther. 3: 849-861; doi: 10.1586/14787210.3.6.849.
35. Pearson RD. 2001. Atovaquone/proguanil for the treatment and prevention of malaria. Curr. Infect. Dis. Rep. 3: 47-49; doi: 10.1007/s11908-001-0058-8.
36. Piperakis SM. 2009. Comet assay: a brief history. Cell. Biol. Toxicol. 25: 1-3; doi: 10.1007/s10565-008-9081-y.
37. Singh NP. 2000. Microgels for estimation of DNA strand breaks, DNA protein crosslinks and apoptosis. Mutat. Res. 455: 111-127; doi: 10.1016/S0027-5107(00)00075-0.
38. Singh NP, McCoy MT, Tice RR, Schneider LL. 1988. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp. Cell Res. 175: 184-191; doi: 10.1016/0014-4827(88)90265-0.
39. Snyder RD, Green JW. 2001. A review of the genotoxicity of marketed pharmaceuticals. Mutat. Res. 488: 151-169; doi: 10.1016/S1383-5742(01)00055-2.
40. Spencer CM, Goa KL. 1995. Atovaquone. A review of its pharmacological properties and therapeutic efficacy in opportunistic infections. Drugs 50: 176-196.
41. Srivastava IK, Morrisey JM, Darrouzet E, Daldal F, Vaidya AB. 1999. Resistance mutations reveal the atovaquone-binding domain of cytochrome b in malaria parasites. Mol. Microbiol. 33: 704-711; doi: 10.1046/j.1365-2958.1999.01515.x.
42. Taylor WR, White NJ. 2004. Antimalarial drug toxicity: a review. Drug. Saf. 27: 25-61; doi: 10.2165/00002018-200427010-00003.
43. Tice RR, Agurell E, Anderson D, Burlinson B, Hartmann A, Kobayashi H, Miyamae Y, Rojas E, Ryu JC, Sasaki YF. 2000. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 35: 206-221; doi: 10.1002/(SICI)1098-2280(2000)35:3<206::AID-EM8>3.0.CO;2-J.
44. Wada S, Khoa TV, Kobayashi Y, Funayama T, Yamamoto K, Natsuhori M, Ito N. 2003. Detection of radiation-induced apoptosis using the comet assay. J. Vet. Med. Sci. 65: 1161-1166; doi: 10.1292/jvms.65.1161.
45. Wiesner J, Ortmann R, Jomaa H, Schlitzer M. 2003. New antimalarial drugs. Angew. Chem. Int. EdN Engl. 42: 5274-5293; doi: 10.1002/anie.200200569.
46. Witte I, Plappert U, de Wall H, Hartmann A. 2007. Genetic toxicity assessment: employing the best science for human safety evaluation part III: the comet assay as an alternative to in vitro clastogenicity tests for early drug candidate selection. Toxicol. Sci. 97: 21-26; doi: 10.1093/toxsci/kfl192.
47. Zhou J, Duan L, Chen H, Ren X, Zhang Z, Zhou F, Liu J, Pei D, Ding K. 2009. Atovaquone derivatives as potent cytotoxic and apoptosis inducing agents. Bioorg. Med. Chem. Lett. 19: 5091-5094; doi: 10.1016/j.bmcl.2009.07.044.